Sickle Cell Disease News Home | Sickle Cell Disease News
WEB5 days ago · Becoming educated and informed about sickle cell disease is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes. Get informed
Bluebird set for Lyfgenia’s launch after ‘remarkable’ approvals
WEBDec 21, 2023 · Bluebird Bio’s Lyfgenia (lovotibeglogene autotemcel) — formerly lovo-cel — was cleared for SCD patients, ages 12 and older, with a history of vaso-occlusive events (VOEs). It was approved along with Casgevy (exagamglogene autotemcel), or exa-cel, from Vertex Pharmaceuticals and CRISPR Therapeutics. “To …
Supporters gearing up to raise awareness for SCD in September
WEBAug 31, 2023 · Advocates, patients, caregivers, doctors and others impacted by sickle cell disease (SCD) are gathering in September to bring attention to the struggles and needs of those living with the condition, and the importance of research and developing treatments.
About Us – Sickle Cell Disease News
WEBSickle Cell Disease News is a digital platform intended to provide the sickle cell disease (SCD) community with the most recent news and information on SCD, as well as first-hand community perspectives from our patient and caregiver columnists.
FDA approves lovo-cel, now Lyfgenia, for sickle cell disease
WEBDec 8, 2023 · The U.S. Food and Drug Administration (FDA) has approved lovotibeglogene autotemcel, a gene therapy from Bluebird Bio known as lovo-cel, for treating sickle cell disease (SCD) patients ages 12 and older who have a history of vaso-occlusive events (VOEs), including painful vaso-occlusive crises (VOCs), acute …
FDA approves Casgevy, 1st CRISPR therapy for sickle cell disease
WEBDec 8, 2023 · The U.S. Food and Drug Administration (FDA) has approved the gene-editing therapy exagamglogene autotemcel (exa-cel) — now known as Casgevy — for treating sickle cell disease (SCD). The therapy from Vertex Pharmaceuticals and CRISPR Therapeutics is indicated for patients ages 12 and older …
Etavopivat for sickle cell disease | Sickle Cell Disease News
WEBJun 29, 2024 · A Phase 1/2 clinical trial (NCT06198712) is testing the safety and efficacy of etavopivat in up to 50 adolescents with SCD, ages 12-18. Patients will take etavopivat as tablets once daily for 96 weeks, or nearly two years. The last visit will take place four weeks after the end of treatment.
Top 10 Sickle Cell Disease Stories of 2022 | Sickle Cell Disease News
WEBDec 29, 2022 · Sickle cell disease (SCD), Top 10. Sickle Cell Anemia News brings you coverage of the latest developments in research and advances in treatment for sickle cell disease in 2022.
News Archives - Sickle Cell Disease News
WEB‘Sickle Cell Matters’ during Sickle Cell Awareness Month. The sickle cell disease (SCD) community will mark National Sickle Cell Awareness Month through September to help bring greater visibility to the inherited blood disorder and the …
Approved treatments for sickle cell disease
WEBSickle cell disease (SCD) may be cured in some individuals by a stem cell transplant. There also are several approved therapies to help manage the condition and its related complications. Some of the approved therapies used …